Genprex issues 2025 corporate update; two lung cancer trials ongoing

Genprex, Inc.

Patient treatment continues in two lung cancer clinical trials.
Company highlights clinical milestones across oncology and diabetes programs.
CEO Ryan Confer cites progress and upcoming milestones for H2 2025 and beyond.
No specific financial results or enrollment numbers disclosed.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.